Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has released an insightful update detailing its business progress and future objectives for 2025. The company focuses on developing innovative therapies aimed at overcoming cancer drug resistance and immune suppression, critical challenges in oncology.
In a recent letter to shareholders, Kairos Pharma’s management team highlighted significant milestones achieved in 2024, which laid a robust foundation for the company’s future endeavors. The past year was pivotal as the organization prepared to enter public markets while advancing its scientific initiatives.
The company achieved several significant milestones that underscored its growth and innovation. Notably, it successfully closed its Initial Public Offering (IPO) and listed its common stock on the NYSE American on September 16, marking a pivotal moment in its trajectory. Additionally, a collaboration with PreCheck Health Services was established to develop a biomarker panel aimed at identifying patients responsive to ENV105, specifically addressing drug resistance in prostate and lung cancer.
The company also expanded its clinical trials by adding the City of Hope Cancer Center to the Phase 2 trial for ENV105, which focuses on castrate-resistant prostate cancer. Furthermore, the first patient was dosed in a combination therapy trial involving ENV105 and Osimertinib, aimed at enhancing treatment sensitivity for EGFR-driven lung cancer. Investor engagement was robust, with participation in various conferences and the initiation of research coverage by industry leaders such as Jason Kolbert from EF Hutton and Tony Butler from Rodman and Renshaw. In terms of funding, Kairos Pharma completed a PIPE transaction in 2025 that raised $3.5 million to support ongoing clinical trials and the development of preclinical assets. Finally, the company expanded its patent coverage to protect its technologies both domestically and internationally.
This year Kairos Pharma looks to build on a solid foundation established in the previous year. The company will continue its Phase 2 randomized clinical trial of ENV105 for prostate cancer and a Phase 1 trial for non-small cell lung cancer (NSCLC). Interim safety data from these trials is expected, with results from the prostate cancer trial anticipated in the first half of 2025 and NSCLC data by year-end. Additionally, Kairos plans to present findings at national scientific meetings to enhance its visibility within the research community.
Further developments include conducting pre-Investigational New Drug (IND) studies for KROS 101, which will also be published. The company aims to explore potential partnerships as part of its strategic growth plan. Overall, Kairos Pharma’s initiatives reflect its commitment to advancing cancer therapeutics and providing significant value to shareholders through ongoing clinical development and data presentation.
Kairos Pharma’s leadership remains optimistic about the transformative potential of its therapeutics. The company’s innovative approach targets CD105, a protein linked to drug resistance, aiming to restore the effectiveness of standard cancer therapies across multiple types.
